Company profile
Immunovant, Inc.
NASDAQ:IMVTBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BATOCLIMAB | phase2 | — | 4 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (19)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07286006 | phase2 | enrolling_by_invitation | 2026-01-26 | 2030-03-01 | Immunovant Sciences GmbH | A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) |
| NCT05907668 | phase2 | completed | 2023-05-15 | 2025-07-25 | Immunovant Sciences GmbH | A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease |
| NCT03863080 | phase2 | completed | 2019-05-21 | 2020-10-07 | Immunovant Sciences GmbH | A Study of RVT-1401 in Myasthenia Gravis (MG) Patients |
| NCT07018323 | phase2 | recruiting | 2025-06-19 | 2027-05-01 | Immunovant Sciences GmbH | A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease |
| NCT06727604 | phase2 | recruiting | 2024-12-17 | 2028-06-01 | Immunovant Sciences GmbH | A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease |
FDA applications (0)
No records yet.